SOTT – Sign Of The Times
By Paul Anthony Taylot
Dr. Rath Health Foundation
Fri, 11 Feb 2022 00:00 UTC
It is no coincidence that the escalation of the crisis in Ukraine comes at a time when, just as the world begins to transition away from polluting fossil fuels, soaring energy prices are forcing millions of people to choose between putting food on the table and heating their homes. Neither is it coincidental that the escalation towards war coincides with experimental mRNA- and DNA-based COVID-19 vaccines directing skyrocketing profits into the bulging pockets of the pharmaceutical industry.
It is already clear that a global transition away from fossil fuels will decimate the current business models of oil and gas producers. But what is less well understood is that the profits of the pharmaceutical industry are now equally at threat. Prior to the COVID-19 pandemic, drug company business models were on the brink of terminal decline. By 2018, researchers examining the industry were predicting that decreasing success rates in new drug development, rising clinical trial costs, and increasing competition from cheaper generic manufacturers could soon combine to result in pharmaceutical production no longer being a profitable business.